Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...

The agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers ...